Aug 18, 2020 · DR-18 mitigates NK cell dysfunction in MHC class I-deficient tumors, leading to efficient cytolysis of malignant cells.

Phase I clinical trials of recombinant human IL-18 have demonstrated that it can be safely administered to patients with advanced cancer. Biologic effects of IL-18 therapy include activation of monocytes, NK cells, and T cells and production of IFN-γ as well as other cytokines in vivo.

Jun 24, 2020 · An engineered version of IL-18 that is resistant to binding by the soluble decoy receptor IL-18BP shows strong anti-tumour activity in mouse models of cancer.

IL-18 bioactivity is chiefly downregulated by a decoy soluble receptor named IL18-binding protein (IL-18BP) that is induced by IFNγ as a negative feedback mechanism. Recent advances indicate promising efficacy of IL-18 at armoring CAR-T cells for the treatment of …

Dec 1, 2013 · IL-18 was identified as an interferon-γ-inducing factor, enhancing the Th1 immune-response by stimulation of natural killer (NK) and cytotoxic T cells. It has been additionally described as an important player in inflammation, autoimmunity and anticancer immune response.

Our study has identified that IL-18 may act as a colon cancer suppressor that inhibit the proliferation of colon cancer cells. These findings highlight the potential of IL-18 as a marker for patient prognosis and a therapeutic target in colon cancer.

Nov 1, 2017 · Interleukin (IL)-18, structurally similar to IL-1β, is a member of IL-1 superfamily of cytokines. This cytokine, which is expressed by many human lymphoid and nonlymphoid cells, has an important role in inflammatory processes.

IL-18 could have a pro-tumoral activity in certain types of cancers, such as in pancreatic cancer and multiple myeloma, as discussed in this review, and the source and frequency of IL-18 release may contribute to its effect.

Dec 11, 2023 · IL-18 agonist treatments that leverage the site of production or subversion of endogenous IL-18 inhibition show promise in augmenting immune responses to cancer.

Dec 2, 2016 · Our findings demonstrate that anti-CD19 CAR T cells that constitutively secrete IL-18 significantly increase serum cytokine secretion, enhance CAR T cell persistence, induce long-term B cell aplasia and improve mouse survival, even without any prior preconditioning.